On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.
Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.
Unlike many large pharmaceutical companies, Sandoz is still investing in antibiotics, most recently through the acquisition of a GSK portfolio and an expansion in European production. This business area will remain central to the company, says Carol Lynch.
US-based pharmaceutical firm MSD has allowed its drug Keytruda to be used for a phase IIb trial conducted by Evaxion. The Danish biotech company will test its own lead candidate against melanoma in combination with MSD's multi-blockbuster drug.
The nitric acid leak at a Novo Nordisk facility in the Danish town of Hillerød has been dealt with, and employees have returned to the building in question, the company informs MedWatch, reporting that the leak hasn't affected production.
The drug Adtralza, which is developed by Leo Pharma, has reached both its primary and secondary endpoints after a 16-week phase III trial testing the eczema treatment in patients with moderate-to-severe atopic dermatitis.
After a short dialog with the authorities and its partner, Sage, Biogen is planning to start the application process for marketing authorization for its depression drug zuranolone in 2022. This is despite the fact that a recent study did not generate overwhelmingly convincing results.
Diamyd Medical has moved up its phase III start date in Europe to avoid potential delays in the patient recruitment process caused by the partial clinical hold in the US, which was implemented by the FDA in September.
Third quarter Roche sales figures exceeded analysts' expectations. Sales in the Roche Group totaled almost CHF 16bn (USD 17.3) in Q3, whereas sales in the diagnostics division amounted to CHF 4.26bn (USD 4.6bn).
Analysts from both US-based Jefferies and Danish bank Sydbank say that the sales forecast for Johnson & Johnson's drug Darzalex, which the company obtained through a licensing agreement with Genmab, is a tad too conservative, perhaps signaling a potential upgrade.
Sales of the Genmab-developed drug Darzalex, which is in-licensed to Jonhson & Johson, have gone so well in the third quarter that one analyst thinks a guidance upgrade from Genmab could likely be on its way.